Compugen presents ovarian cancer trial poster at ESMO meeting
- ByInvesting.com•
Last | High | Low | |||||
|---|---|---|---|---|---|---|---|
| 746.7 | 751.5 | 730.5 | +0.9 | +0.12% | 4.08M | ||
| 23,540 | 23,620 | 22,460 | +430 | +1.86% | 332.5K | ||
| 1,604.0 | 1,625.0 | 1,580.0 | -22.0 | -1.35% | 1.53M | ||
| 79,940 | 80,600 | 78,700 | -1,060 | -1.31% | 53.33K | ||
| 2,962 | 2,985 | 2,868 | +68 | +2.35% | 5.44M | ||
| 232,300 | 244,600 | 232,300 | -9,600 | -3.97% | 41.76K | ||
| 22,400 | 22,560 | 21,890 | +380 | +1.73% | 292K | ||
| 16,300 | 16,320 | 15,620 | +300 | +1.88% | 462.61K | ||
| 1,510 | 1,589 | 1,507 | -59 | -3.76% | 2.62M | ||
| 6,738 | 6,793 | 6,562 | +118 | +1.78% | 8.44M | ||
| 1,700.0 | 1,711.0 | 1,638.0 | +15.0 | +0.89% | 1.91M | ||
| 41,850 | 42,230 | 40,310 | +560 | +1.36% | 41.69K | ||
| 45,660 | 46,030 | 44,550 | +270 | +0.59% | 40.95K | ||
| 20,080 | 20,230 | 19,440 | +400 | +2.03% | 808.92K | ||
| 24,540 | 25,090 | 24,260 | -610 | -2.43% | 200.73K | ||
| 17,070 | 17,090 | 16,260 | +450 | +2.71% | 357.67K | ||
| 6,944 | 7,000 | 6,745 | +143 | +2.10% | 5.36M | ||
| 4,377 | 4,389 | 4,236 | +29 | +0.67% | 231.53K | ||
| 11,880 | 12,040 | 11,570 | +80 | +0.68% | 103.42K | ||
| 9,321 | 9,635 | 9,250 | -214 | -2.24% | 1.01M | ||
| 82,470 | 83,340 | 79,750 | +3,020 | +3.80% | 186.52K | ||
| 56,680 | 56,800 | 53,230 | +2,970 | +5.53% | 80.44K | ||
| 35,200 | 35,580 | 34,000 | +470 | +1.35% | 74.09K | ||
| 168,910 | 172,900 | 165,000 | +2,010 | +1.20% | 48.72K | ||
| 41,520 | 42,040 | 40,580 | 0 | 0.00% | 72.16K | ||
| 69,370 | 69,970 | 67,500 | +520 | +0.76% | 21.55K | ||
| 56,460 | 56,810 | 52,100 | +1,050 | +1.89% | 53.35K | ||
| 25,280.0 | 25,430.0 | 23,350.0 | +1,000.0 | +4.12% | 445.9K | ||
| 20,120 | 20,430 | 19,310 | +180 | +0.90% | 47.36K | ||
| 4,434 | 4,458 | 4,239 | +118 | +2.73% | 606.4K | ||
| 37,750 | 38,070 | 37,090 | +1,120 | +3.06% | 92.51K | ||
| 10,040 | 10,150 | 9,616 | +201 | +2.04% | 780.25K | ||
| 12,150 | 12,420 | 11,940 | -100 | -0.82% | 134.9K | ||
| 13,030 | 13,330 | 12,420 | -260 | -1.96% | 607.7K | ||
| 27,240 | 28,350 | 27,070 | -1,470 | -5.12% | 465.31K |
No Earning Reports have been scheduled